Rahul Khupse

University of Findlay

Hancock County, OH

United States

SCHOLARLY PAPERS

1

DOWNLOADS

462

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Ideas:
“  Targeting Hyper-inflammation in COVID-19 with Bromodomain (BRD-2/4) inhibitors: Acute respiratory distress accompanied by hyper-inflammation is the leading cause of deaths in COVID-19. In stage I (mild infection) the anti-inflammatory therapies can be detrimental. However, in stage III subset of COVID-19 patients, with severe systemic hyper inflammation, the use of immunomodulatory agents may be useful approach. SARS-CoV-2 human protein-protein interaction map revealed bromodomain (BRD) protein as an important drug target. BRD’s serves as readers of lysine acetylation on histones, a key event in transcriptional activation for the immune response. The transmembrane protein E of SARS-CoV-2 shares similarity to N-terminus of histone 2A and disrupts the interaction between BRD-2 and histone, thus inducing transcription of proteins beneficial to the virus. This virus-host protein interaction can be interrupted by using BRD-2/4 inhibitors.  ”

Scholarly Papers (1)

1.

Potential Antiviral Mechanism of Hydroxychloroquine in COVID-19 and Further Extrapolation to Celecoxib (Celebrex) for Future Clinical Trials.

Number of pages: 8 Posted: 07 Apr 2020
Rahul Khupse and Pankaj Dixit
University of Findlay and Indore Institute of Pharmacy
Downloads 462 (73,754)
Citation 1

Abstract:

Loading...

COVID-19, Hydroxychloroquine, Celcoxib, BRD, Mechanism